What is the current Price Target for the Relmada Therapeutics Inc stock?

The average Relmada Therapeutics Inc target price is $12.24. This is 197.09% higher than the current stock price. The highest price target is 384.22%, the lowest is 120.63%. 8 Analysts have issued a price target Relmada Therapeutics Inc 2027 .

How high will the Relmada Therapeutics Inc stock rise?

No reliable answer can be given as to how high the Relmada Therapeutics Inc stock will rise. The performance of stocks, including the Relmada Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Relmada Therapeutics Inc stock today?

The performance of Relmada Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Relmada Therapeutics Inc stock fall?

The decline in Relmada Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Relmada Therapeutics Inc Forecast, price target & analysts

$4.12

1.90%

Nasdaq, Sep 18, 04:00 pm EDT. Closed.

ISIN

US75955J2042

Symbol

RLMD

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Analysts Charts Ownership News Strategies

Relmada Therapeutics Inc Target price 2026 - Analyst rating & recommendation

Relmada Therapeutics Inc Classifications & Recommendation

Buy

91%

Hold

Relmada Therapeutics Inc Price Target

Target Price	$12.24
Price	$4.12
Potential	197.09% register free of charge
Number of Estimates	8

	8 Analysts have issued a price target Relmada Therapeutics Inc 2027 . The average Relmada Therapeutics Inc target price is $12.24. This is 197.09% register free of charge higher than the current stock price. The highest price target is $19.95 384.22% register free of charge , the lowest is $9.09 120.63% register free of charge .
	A rating was issued by 11 analysts: 10 Analysts recommend Relmada Therapeutics Inc to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Relmada Therapeutics Inc stock has an average upside potential 2027 of 197.09% register free of charge . Most analysts recommend the Relmada Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '25	2026 Estimates
Earnings Per Share $	-1.45	-0.66
	45.28%	54.48%
P/E		negative

8 Analysts have issued a Relmada Therapeutics Inc forecast for earnings per share. The average Relmada Therapeutics Inc EPS is

unlock

. This is

unlock

than earnings per share in the financial year 2025. The highest EPS forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics and future valuations:

2025	$-1.45	45.28%
2026	$-0.66 54.48% unlock
2027	$-0.83 25.76% unlock
2028	$-0.83 0.00% unlock
2029	$-0.84 1.20% unlock
2030	$-0.24 71.43% unlock
2031	$1.10 558.33% unlock
2032	$2.52 129.09% unlock
2033	$4.30 70.63% unlock

Current	-7.49	865.82%
2026	-6.27 16.30% unlock
2027	-4.99 20.41% unlock
2028	-4.99 0.00% unlock
2029	-4.93 1.20% unlock
2030	-16.83 241.38% unlock
2031	3.74 122.22% unlock
2032	1.64 56.15% unlock
2033	0.96 41.46% unlock

Relmada Therapeutics Inc...

Current Relmada Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
HC Wainwright & Co.	Locked ➜ Locked	Locked	Jun 18 2026
Piper Sandler	Locked ➜ Locked	Locked	Mar 24 2026
Mizuho	Locked ➜ Locked	Locked	Mar 20 2026
LUCID CAPITAL MARKETS	Locked ➜ Locked	Locked	Mar 02 2026
Leerink Partners	Locked ➜ Locked	Locked	Jan 23 2026
Jefferies	Locked ➜ Locked	Locked	Dec 22 2025
Mizuho	Locked ➜ Locked	Locked	Nov 19 2025

Analyst Rating	Date
Locked HC Wainwright & Co.: Locked ➜ Locked	Jun 18 2026
Locked Piper Sandler: Locked ➜ Locked	Mar 24 2026
Locked Mizuho: Locked ➜ Locked	Mar 20 2026
Locked LUCID CAPITAL MARKETS: Locked ➜ Locked	Mar 02 2026
Locked Leerink Partners: Locked ➜ Locked	Jan 23 2026
Locked Jefferies: Locked ➜ Locked	Dec 22 2025
Locked Mizuho: Locked ➜ Locked	Nov 19 2025

Discover more stocks with a high price target

NIO ADR 100.10%

Alibaba Group Holding Ltd 68.75%

Infineon 65.25%

Tencent Holdings Ltd. 63.10%

Rheinmetall 61.30%

TUI 56.70%

Adyen 53.16%

Siemens Energy 49.14%

Adidas 46.64%

Uber Technologies 46.13%

BYD 40.95%

NVIDIA 37.67%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now